Literature DB >> 13721953

Immunologic production of antiangiotensin. I. Preparation of angiotensin-protein complex antigen.

S D DEODHAR.   

Abstract

Angiotensin II was coupled with bovine gamma-globulin (BGG) through the following series of reactions. See PDF for Structure By determinations of the aromatic amine and tyrosine contents of p-aminobenzoylangiotensin II, the number of p-aminobenzoyl residues introduced per molecule of angiotensin II was calculated. Absorption spectra (between 250 and 500 mmicro) of BGG complexes of p-aminobenzoylangiotensin II and six different para substituted aromatic amines were compared. Specific activities (dog units/millimicromole) of the different intermediate products were determined. Presence of a terminal, free amino group does not appear to be an absolute requirement for the biological activity of angiotensin II, since substitution of a p-aminobenzoyl radical in this group yields a product with 40 to 50 per cent of the activity of the parent compound. Angiotensin I, on the other hand, is completely inactivated under identical circumstances. Possible implication of this finding has been discussed.

Entities:  

Keywords:  HYPERTENSIN/antagonists; PROTEINS/chemistry

Mesh:

Substances:

Year:  1960        PMID: 13721953      PMCID: PMC2137262          DOI: 10.1084/jem.111.3.419

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  Studies on renin antibodies.

Authors:  O M HELMER
Journal:  Circulation       Date:  1958-04       Impact factor: 29.690

2.  Studies on antirenin.

Authors:  H LAMFROM; E HAAS; H GOLDBLATT
Journal:  Am J Physiol       Date:  1954-04

3.  Physiological properties of renin and hypertension.

Authors:  H GOLDBLATT; H LAMFROM; E HAAS
Journal:  Am J Physiol       Date:  1953-10

4.  The substance causing renal hypertension.

Authors:  E Braun-Menendez; J C Fasciolo; L F Leloir; J M Muñoz
Journal:  J Physiol       Date:  1940-07-24       Impact factor: 5.182

5.  Antirenin in man and animals.

Authors:  H GOLDBLATT; E HAAS; H LAMFROM
Journal:  Trans Assoc Am Physicians       Date:  1951

6.  The preparation and function of the hypertensin-converting enzyme.

Authors:  L T SKEGGS; J R KAHN; N P SHUMWAY
Journal:  J Exp Med       Date:  1956-03-01       Impact factor: 14.307

7.  The amino acid sequence of hypertensin. II.

Authors:  L T SKEGGS; K E LENTZ; J R KAHN; N P SHUMWAY; K R WOODS
Journal:  J Exp Med       Date:  1956-08-01       Impact factor: 14.307

8.  ON THE SEROLOGICAL SPECIFICITY OF PEPTIDES. II.

Authors:  K Landsteiner; J van der Scheer
Journal:  J Exp Med       Date:  1934-05-31       Impact factor: 14.307

9.  ON THE SEROLOGICAL SPECIFICITY OF PEPTIDES.

Authors:  K Landsteiner; J van der Scheer
Journal:  J Exp Med       Date:  1932-04-30       Impact factor: 14.307

  9 in total
  5 in total

1.  [Angiotensin].

Authors:  F GROSS
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1963

2.  Production of antibodies against synthetic angiotensin II in various animal species.

Authors:  P R Hedwall; F M Dietrich
Journal:  Experientia       Date:  1967-11-15

3.  Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approach.

Authors:  A R Christlieb; T U Biber; R B Hickler
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

4.  PRODUCTION OF ANTIRENIN TO HOMOLOGOUS RENIN AND ITS EFFECT OF EXPERIMENTAL RENAL HYPERTENSION.

Authors:  S D DEODHAR; E HAAS; H GOLDBLATT
Journal:  J Exp Med       Date:  1964-03-01       Impact factor: 14.307

5.  Immunologic production of antiangiotensin. II. Production and detection of antiangiotensin.

Authors:  S D DEODHAR
Journal:  J Exp Med       Date:  1960-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.